@article {WILLS6429, author = {BEATRIZ WILLS and ANDR{\'E}S F. CARDONA and LEONARDO ROJAS and ALEJANDRO RUIZ-PATI{\~N}O and OSCAR ARRIETA and NOEM{\'I} REGUART and HERN{\'A}N CARRANZA and CARLOS VARGAS and JORGE OTERO and LUIS CORRALES and CLAUDIO MART{\'I}N and MAURICIO CUELLO and LUIS EDUARDO PINO and CHRISTIAN ROLFO and RAFAEL ROSELL and ZYANYA LUCIA ZATARAIN-BARR{\'O}N and on behalf of The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)}, title = {Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab}, volume = {37}, number = {11}, pages = {6429--6436}, year = {2017}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Heavily treated patients with non-small cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. Patients and Methods: A total of 49 patients with heavily treated NSCLC were enrolled from 2011-2014 and treated with irinotecan and bevacizumab. Treatment response along with mutational status of epidermal growth factor receptor (EGFR), and tissue inhibitor of metalloproteinases-1 (TIMP1) and EGFR expression were evaluated. Progression-free (PFS) and overall (OS) survival were monitored. Results: Median follow-up was 13.2 months. Twenty-three patients had received three or more prior therapy lines. Overall response rate was 32\% [95\% confidence interval (CI)=22\%-39\%] and 26\% of patients achieved stable disease. Median PFS was 4.4 (95\% CI=2.8-8.3) months and median OS 18.0 (95\% CI=16.2-30.7) months. Nine patients harboring EGFR mutations had a long-lasting partial response. A shorter OS was found in patients with a higher TIMP1 expression (p=0.006). Conclusion: Irinotecan combined with bevacizumab had favorable antitumor activity in heavily pretreated patients with NSCLC. These results suggest this is a reasonable strategy, particularly for patients with low TIMP1 expression.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/37/11/6429}, eprint = {https://ar.iiarjournals.org/content/37/11/6429.full.pdf}, journal = {Anticancer Research} }